MedTrace Logo

Effects of Gongs Mobilization vs Reverse Distraction Technique in Diabetic Patients With Adhesive Capsulitis

NCT06913361 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-04-06

No results posted yet for this study

Summary

Adhesive capsulitis (AC) represents a renowned musculoskeletal condition which has been clinically classified as frozen shoulder (FS). Adhesive capsulitis occurs 3-5% of the time in the general population, but in diabetics, the frequency can reach 20%. This study is being conducted to determine the effects of gongs mobilization vs reverse distraction technique in diabetic patients with adhesive capsulitis. This study will be a randomized control trial and data will be collected from Haq Orthopedic Hospital. Sample size is 20 calculated by using G power and adding 20 % attrition.

Conditions

  • Adhesive Capsulitis

Interventions

DIAGNOSTIC_TEST

Gongs Mobilization

The treatment begins with moist heat for 10 minutes, Gong's mobilization with conventional therapy for 8 minutes. The total treatment time was 45 minutes once a day for four days per week for four weeks.

COMBINATION_PRODUCT

Reverse Distraction Technique

The treatment begins with moist heat for 10 minutes, Reverse Distraction technique with conventional therapy for 8 minutes. The total treatment time was 45 minutes once a day for four days per week for four weeks. Position of the patient: side-lying. The patient is lying at the plinth's edge on the unaffected side. In front of the patient is the therapist's position.

Sponsors & Collaborators

  • Superior University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-20
Primary Completion
2025-06-20
Completion
2026-02-10

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06913361 on ClinicalTrials.gov